×

Dr. Tushar Kumar Mohapatra

Dr. Tushar Kumar Mohapatra

Dr. Tushar Kumar Mohapatra

QualificationMBBS, MD (Nuclear Medicine)

Specialities Nuclear Medicine And PET

Locations HCG Cancer Center - Cuttack
Book an Appointment

Introduction

Dr. Tushar Kumar Mohapatra is an experienced oncologist specializing in diagnostics, therapeutic intervention, radiation safety and tele-radiologic reporting. He has a special interest in PET CT studies, PET-based radiotherapy planning, iodine therapy, and more. He is also experienced in performing procedures like SISCOS and SISCOM on epilepsy patients. He is a highly respected professional in the field and is known for his expertise in oncology.

Area of Expertise

  • Dr. Mohapatra is experienced in diagnostics, therapeutic intervention, radiation safety and tele-radiologic reporting, with a special interest in F-18, FDG, PET-CT studies for oncology, cardiology, neurology indications, PET-based radiation therapy planning, I-131 therapy in thyroid cancer and benign thyroid diseases, Rhenium-188 for synovectomy and Samarium therapy for bone pain palliation.
  • Dr. Mohapatra is actively involved in performing procedures like SISCOS and SISCOM on epilepsy patients.
  • Dr. Mohapatra has attended more than 40000 cases so far.                              

Research & Publications

  • (18)F-FDG PET/CT for initial assessment and response monitoring in a case of high-grade primary lymphoma of the thyroid gland: A case report and review of the literature. Indian J Nucl Med. 2014 Apr;29(2):94-6.
  • Coexisting iodine avid and iodine non-concentrating lesions with multiple distant soft tissue metastasis in papillary thyroid cancer. Indian J Nucl Med. 2012 Jan;27(1):38-41.
  • Primary penile lymphoma: the use of PET-CT for accurate staging and response monitoring. Diagn Interv Radiol. 2013 Mar-Apr;19(2):130-3.
  • A rare case of mature teratoma. Has FDG PET/CT a role to play? Indian J Nucl Med. 2011 Apr;26(2):107-8.
  • Increased renal corticomedullary FDG activity in a patient of NHL-malignant or benign? Indian J Nucl Med. 2010 Oct;25(4):178.           

Medical Breakthrough

  • Dr. Mohapatra is also a lifetime member of the Society of Nuclear Medicine, India (SNMI) (M-72), and the World Federation of Nuclear Medicine and Biology (WFNMB).  

Other Doctors